Characterizing the metabolic divide: distinctive metabolites differentiating CAD-T2DM from coronary artery disease (CAD) patients
Authors' conclusion
This research underscores the metabolic disparities between CAD and CAD-T2DM patients, spotlighting the protective attributes of pipecolinic acid and L-pipecolic acid. The comprehensive metabolomic and transcriptomic findings provide novel insights into the mechanism research, prophylaxis and treatment of comorbidity of CAD and T2DM.
Study context
- Population
- Patients with CAD with or without T2DM, three centers
- Comparison
- CAD-T2DM vs CAD
- Outcome
- Plasma metabolites associated with T2DM risk
Methodological detailsmulticentre (three centers), discovery and validation cohorts, metabolomic and lipidomic analyses, hepatocyte cellular experiments, transcriptomic analyses
- Multicentre (three centers)
- Discovery and validation cohorts
- Metabolomic and lipidomic analyses
- Hepatocyte cellular experiments
- Transcriptomic analyses
Main finding
As reported in the abstract
Significantly altered profiles associated with T2DM risk (univariate logistic regression), discovery cohort (FDR < 0.05)
192
Significantly altered profiles associated with T2DM risk (univariate logistic regression), validation cohort (P < 0.05)
95
Characteristic metabolites consistently associated with T2DM risk in both cohorts (multivariate regression)
22
Observational data: associations, not effects.
Further findings
Mechanistic experiments
- Pipecolinic acid and L-pipecolic acid influenced cellular glucose metabolism in hepatocytes
- Transcriptomic analyses shed light on potential metabolic action sites of these metabolites
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →